Physician

James Edward Butrynski, M.D.

According to 2025 Medicare claims, James Butrynski, M.D. (NPI: 1427134287) practices medical oncology in the Eugene-Springfield, OR market, with the plurality of this provider's patient population coming from Lane, OR. This provider's primary affiliated billing organization is ONCOLOGY ASSOCIATES OF OREGON P C (NPI: 1013989854; TIN: 930746296) and primary practice location at 97477-8802.

Butrynski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 469 traditional Medicare patients, billed 66,001 HCPCS/CPT codes, and received $1,207,425 in Medicare payments. The top billing code was 99212 (Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more). Part D data shows 1,256 prescription claims across 226 beneficiaries totaling $2,369,557 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2023 DME data shows 12 claims. Open Payments data shows 63 records totaling $190,816. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $134,974 to $1,207,425. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $638,473 to $2,369,557. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	281	2,503	$134,974
2016	343	2,019	$122,915
2017	345	29,210	$491,728
2018	342	60,430	$1,107,316
2019	409	76,924	$1,400,279
2020	456	92,358	$1,423,154
2021	453	77,074	$1,435,672
2022	487	83,993	$1,778,558
2023	472	85,506	$1,584,359
2024	469	66,001	$1,207,425

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	133	784	$638,473
2016	146	913	$677,124
2017	138	716	$441,617
2018	116	600	$343,516
2019	142	705	$668,752
2020	166	894	$2,003,939
2021	158	739	$1,660,155
2022	177	840	$1,818,965
2023	186	949	$1,858,108
2024	226	1,256	$2,369,557

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$46,310
2016	N/R	N/R	N/R
2017	N/R	28	$9,855
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	24	$1,768
2022	N/R	N/R	N/R
2023	N/R	12	$85
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	139	271	$40
80053	Blood test, comprehensive group of blood chemicals	262	685	$10
36415	Insertion of needle into vein for collection of blood sample	268	688	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	263	729	$8
83615	Lactate dehydrogenase (enzyme) level	165	419	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	32	960	$332,889
Tasigna	Nilotinib Hcl	12	336	$238,104
Xtandi	Enzalutamide	16	480	$232,877
Imbruvica	Ibrutinib	11	308	$181,681
Gavreto	Pralsetinib	13	390	$149,081

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$823	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	60	$189,993	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Edward Butrynski, M.D.?

Tedicare shows public-source Medicare data for James Edward Butrynski, M.D. (NPI 1427134287), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Edward Butrynski, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James Edward Butrynski, M.D.?

James Edward Butrynski, M.D. is linked to ONCOLOGY ASSOCIATES OF OREGON P C (billing NPI 1013989854) in the available physician profile data.

Does James Edward Butrynski, M.D. have Open Payments data?

James Edward Butrynski, M.D. has 63 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.